Literature DB >> 22989780

Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke.

Sheng-Feng Sung1, Yu-Wei Chen, Mei-Chiun Tseng, Cheung-Ter Ong, Huey-Juan Lin.   

Abstract

OBJECTIVE: Atrial fibrillation (AF) is associated with poor outcome after intravenous thrombolysis probably due to greater pretreatment stroke severity. We conducted this retrospective study to determine whether AF is an independent predictor for clinical outcome in patients stratified by initial stroke severity.
METHODS: A total of 143 acute ischemic stroke patients who received intravenous thrombolysis within 3h after onset were enrolled. The patients were categorized according to the baseline stroke severity by National Institute of Health Stroke Scale (NIHSS) score (≤10 vs. >10) and the presence of AF or not. Favorable 90-day outcome was defined as a modified Rankin Scale (mRS) score<2.
RESULTS: Among the 100 patients with severe stroke (NIHSS>10), those with AF (n=52) had a higher proportion of favorable 90-day outcome than those without AF (31% vs. 8%, P=0.005). After adjustment for age, baseline glucose level, and onset to treatment time, the difference remained significant (odds ratio 5.80, 95% confidence interval 1.63-20.68). In patients with mild stroke (NIHSS≤10), no difference in clinical outcome was found between AF (n=20) and non-AF (n=23) groups.
CONCLUSION: Presence of AF was associated with favorable 90-day outcome following intravenous thrombolysis in patients with severe stroke at baseline, while the association did not exist in patients with mild stroke.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989780     DOI: 10.1016/j.clineuro.2012.08.034

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

1.  Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia.

Authors:  Visnja Padjen; Marie Bodenant; Dejana R Jovanovic; Nelly Ponchelle-Dequatre; Novak Novakovic; Charlotte Cordonnier; Ljiljana Beslac-Bumbasirevic; Didier Leys
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

2.  Age Predicts Functional Outcome in Acute Stroke Patients with rt-PA Treatment.

Authors:  Jarin Chindaprasirt; Kittisak Sawanyawisuth; Paiboon Chattakul; Panita Limpawattana; Somsak Tiamkao; Patcharin Aountri; Verajit Chotmongkol
Journal:  ISRN Neurol       Date:  2013-09-19

Review 3.  Atrial Fibrillation is Associated With Poor Outcomes in Thrombolyzed Patients With Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.

Authors:  Rongzheng Yue; Dongze Li; Jing Yu; Shuangshuang Li; Yan Ma; Songmin Huang; Zhi Zeng; Rui Zeng; Xiaolin Sun
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

4.  Controlling Hypertension After Severe Cerebrovascular Event (CHASE): study protocol for a randomized controlled trial.

Authors:  Fang Yuan; Fang Yang; Changhu Xue; Kangjun Wang; Qiuwu Liu; Jun Zhou; Feng Fu; Xiaocheng Wang; Wei Zhang; Yi Liu; Kang Huo; Hua Lv; Wen Jiang
Journal:  Trials       Date:  2018-02-21       Impact factor: 2.279

5.  Efficacy and safety of thrombolysis for acute ischemic stroke with atrial fibrillation: a meta-analysis.

Authors:  Yunzhen Hu; Chunmei Ji
Journal:  BMC Neurol       Date:  2021-02-11       Impact factor: 2.474

6.  The prognostic significance of large vessel occlusion in stroke patients treated by intravenous thrombolysis.

Authors:  Justyna M Derbisz; Marcin Wnuk; Tadeusz Popiela; Jeremiasz Jagiełła; Roman Pułyk; Joanna Słowik; Tomasz Dziedzic; Wojciech Turaj; Agnieszka Słowik
Journal:  Pol J Radiol       Date:  2021-06-11

7.  Similar thrombolysis outcomes in acute stroke patients with and without atrial fibrillation if pre-stroke CHA2DS2-VASc score is low: A retrospective study.

Authors:  Hung-Ming Wu; Chih-Ping Chung; Yung-Yang Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.